Lexaria Bioscience Corp (LEXX)vsBeiGene, Ltd. (ONC)

LEXX

Lexaria Bioscience Corp

NASDAQ

$0.77

-0.92%

HEALTHCARE · Cap: $18.17M

ONC

BeiGene, Ltd.

NASDAQ

$283.45

+2.81%

HEALTHCARE · Cap: $31.62B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

BeiGene, Ltd. generates 1023470% more annual revenue ($5.34B vs $522,000). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).

LEXX

Avoid

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0

ONC

Hold

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 3.0Quality: 6.5

Piotroski: 5/9Altman Z: 0.26

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LEXX.

ONCSignificantly Overvalued (-1983.5%)

Margin of Safety

-1983.5%

Fair Value

$16.86

Current Price

$283.45

$266.59 premium

UndervaluedFair: $16.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LEXX1 strengths · Avg: 10.0/10

Revenue GrowthGrowth

107.1%10/10

Revenue surging 107.1% year-over-year

ONC2 strengths · Avg: 9.5/10

Revenue GrowthGrowth

32.8%10/10

Revenue surging 32.8% year-over-year

Debt/EquityHealth

0.259/10

Conservative balance sheet, low leverage

Areas to Watch

LEXX4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$18.17M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Return on EquityProfitability

-1.6%2/10

ROE of -1.6% — below average capital efficiency

ONC4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Return on EquityProfitability

7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability

5.4%3/10

5.4% margin — thin

P/E RatioValuation

111.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : LEXX

The strongest argument for LEXX centers on Revenue Growth. Revenue growth of 107.1% demonstrates continued momentum.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.

Bear Case : LEXX

The primary concerns for LEXX are EPS Growth, Market Cap, Profit Margin.

Bear Case : ONC

The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.

Key Dynamics to Monitor

LEXX carries more volatility with a beta of 0.56 — expect wider price swings.

LEXX is growing revenue faster at 107.1% — sustainability is the question.

ONC generates stronger free cash flow (131M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ONC scores higher overall (42/100 vs 25/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lexaria Bioscience Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Lexaria Bioscience Corp. The company is headquartered in Kelowna, Canada.

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Compare with Other BIOTECHNOLOGY Stocks

LEXX vs VRTX LEXX vs REGN LEXX vs ARGX LEXX vs ALNY LEXX vs INSM ONC vs VRTX ONC vs REGN ONC vs ARGX ONC vs ALNY ONC vs INSM

Want to dig deeper into these stocks?

Full LEXX Analysis →Full ONC Analysis →